Tivozanib

Tivozanib
Clinical data
Trade namesFotivda
Other namesAV-951
AHFS/Drugs.comMonograph
MedlinePlusa621018
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding>99%
Elimination half-life4.5–5.1 days
Excretion79% feces, 12% urine
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H19ClN4O5
Molar mass454.87 g·mol−1
3D model (JSmol)
  • O=C(Nc1noc(c1)C)Nc4ccc(Oc2c3cc(OC)c(OC)cc3ncc2)cc4Cl
  • InChI=InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
  • Key:SPMVMDHWKHCIDT-UHFFFAOYSA-N

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).[3] It is an oral VEGF receptor tyrosine kinase inhibitor.[3]

The most common side effects include fatigue (tiredness), hypertension (high blood pressure), diarrhea, decreased appetite, nausea, dysphonia (voice changes), hypothyroidism, cough, and stomatitis.[4][3][5]

Tivozanib was approved for medical use in the European Union in August 2017,[4] and in the United States in March 2021.[3][5]

  1. ^ "Fotivda 890mcg hard capsules Summary of Product Characteristics (SmPC)". (emc). 4 April 2023. Archived from the original on 6 April 2023. Retrieved 23 July 2023.
  2. ^ "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
  3. ^ a b c d e "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  4. ^ a b c "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ a b Cite error: The named reference Fotivda FDA snapshot was invoked but never defined (see the help page).